Compare Amylx Pharmaceuticals Inc (AMLX) vs NRG Energy Inc (NRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs NRG Energy Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.84 (market cap $2.64B), while NRG Energy Inc trades at $122.36 (market cap $24.83B). The key difference: NRG Energy Inc is far larger — about 9.4× Amylx Pharmaceuticals Inc's market cap, and NRG Energy Inc pays a 1.61% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | NRG | |
|---|---|---|
Market Cap | $2.64B | $24.83B |
Sector | Health | Utilities |
52-Week High | $24.19 | $184.03 |
52-Week Low | $7.82 | $117.04 |
Enterprise Value | $2.39B | $48.79B |
Dividend Yield | — | 1.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.
Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.
NRG Energy trades at $118.91, down 0.66% today, with a bearish technical signal. Recent Q2 2026 earnings missed estimates, but revenue grew 11% year-over-year. The company is expanding with a 1.2 GW Texas data-center power project, targeting long-term EBITDA growth. Valuation metrics show a P/E of 30.76 and P/S of 0.72, with strong ROE at 26.77% but modest net income margin of 2.56%. Cash flow trends are volatile, with 2025 net cash flow at $3.83B but a projected decline in 2026.
Outlook: Growth driven by data-center demand and strategic acquisitions offers upside, but high debt and earnings misses pose risks. Analyst consensus is bullish with a $207.83 price target, though technical weakness and rising interest costs require caution. Key opportunities include hyperscaler partnerships, while risks involve leverage and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →
